Exagen (XGN) Cash & Equivalents (2018 - 2026)

Exagen (XGN) has reported Cash & Equivalents for 9 consecutive years, with $21.5 million the latest figure, recorded in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $21.5 million, up 92.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.5 million (up 92.18% YoY), and the FY2025 annual result was $32.2 million, up 46.22% from the prior year.
• Cash & Equivalents was $21.5 million for Q1 2026 at Exagen, down from $32.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $89.8 million in Q1 2022 and troughed at $11.2 million in Q1 2025.
• Average Cash & Equivalents over 5 years is $39.5 million, with a median of $31.5 million recorded in 2023.
• Year-over-year, Cash & Equivalents tumbled 59.0% in 2025 and soared 92.18% in 2026.
• Over 5 years, Cash & Equivalents stood at $62.4 million in 2022, then slumped by 41.51% to $36.5 million in 2023, then slumped by 39.62% to $22.0 million in 2024, then soared by 46.22% to $32.2 million in 2025, then tumbled by 33.23% to $21.5 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $21.5 million in Q1 2026, $32.2 million in Q4 2025, and $35.7 million in Q3 2025.